Join Conscio Group upcoming webinar on December 12 at 2:00 PM CET (expected length up to 2 hours), where industry experts will discuss the latest trends in regulation, R&D and clinical testing. In our session we will particularly explore potential regulatory changes regarding the waiver of Phase 3 efficacy studies.
Topics include:
- Navigating Biosimilar Regulations: Evolution, Challenges, and Future Directions
- Common pitfalls on the path from R&D to biotech product commercialization
- Strategies for successful bioassay transfer and validation – the importance of standardization
Speakers: Elena Guillen Benitez, MD, PhD from Leiden University Medical Center, Martin Baur from Midas Pharma, and Klemens Weitenthaler from Conscio Group.
Moderator: Stephan Holl, CEO Conscio Group
Gain insider knowledge on the biosimilar industry – register here!
If you would like to view the recording of the webinar, please contact us today and we will be happy to give you exclusive access to it on our YouTube channel.
